Which statement correctly describes Leflunomide?

Prepare for the Dermatology Week 1 Exam with comprehensive study materials. Practice with detailed questions, flashcards, and expert explanations. Boost your knowledge and confidence for the exam!

Multiple Choice

Which statement correctly describes Leflunomide?

Explanation:
Leflunomide is a disease-modifying antirheumatic drug that works by blocking de novo pyrimidine synthesis. It is a prodrug (converted to the active teriflunomide) that inhibits dihydroorotate dehydrogenase, reducing production of pyrimidines and thereby limiting the proliferation of activated T and B lymphocytes. This mechanism underlies its use in rheumatoid arthritis. Its brand name is Arava. It is not a monoclonal antibody against TNF (that describes anti-TNF biologics like infliximab or adalimumab), and it is not an NSAID. It specifically targets pyrimidine synthesis, not purine synthesis.

Leflunomide is a disease-modifying antirheumatic drug that works by blocking de novo pyrimidine synthesis. It is a prodrug (converted to the active teriflunomide) that inhibits dihydroorotate dehydrogenase, reducing production of pyrimidines and thereby limiting the proliferation of activated T and B lymphocytes. This mechanism underlies its use in rheumatoid arthritis. Its brand name is Arava. It is not a monoclonal antibody against TNF (that describes anti-TNF biologics like infliximab or adalimumab), and it is not an NSAID. It specifically targets pyrimidine synthesis, not purine synthesis.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy